| Literature DB >> 32123226 |
Hyung Seok Lee1,2, Mi Jin Park2, Sam Youl Yoon3, Narae Joo1,2, Young Rim Song1,2, Hyung Jik Kim1, Sung Gyun Kim1,2, Victor Nizet4, Jwa-Kyung Kim5,6,7.
Abstract
The functional quality of the inflow artery is one of the most important determinants of arteriovenous fistula (AVF) success. We evaluated the association of early optimal brachial arterial dilatation with a successful AVF maturation and assessed the role of peribrachial adipose tissue in determining brachial arterial distensibility. All patients underwent a preoperative vascular mapping with Doppler ultrasound (US), and only patients who had suitable vessels for AVF creation were enrolled (n = 162). Peribrachial fat thickness was measured using US. To evaluate the degree of brachial dilatation, follow-up US was performed at 1 month after surgery, and early brachial artery dilation was defined as the change in postoperative arterial diameter compared to the preoperative value. The primary outcome was failure to achieve a clinically functional AVF within 8 weeks. Nonfunctional AVF occurred in 21 (13.0%) patients, and they had a significantly lower brachial dilatation than patients with successful AVF during early period after surgery (0.85 vs. 0.43 mm, p = 0.003). Patients with a brachial dilatation greater than median level showed a 1.8-times higher rate of achieving a successful AVF than those without. Interestingly, the early brachial dilatation showed significant correlations with diabetes (r = -0.260, p = 0.001), peribrachial fat thickness (r = -0.301, p = 0.008), and the presence of brachial artery calcification (r = -0.178, p = 0.036). Even after adjustments for demographic factors, comorbidities, and baseline brachial flow volume, peribrachial fat thickness was an independent determinant for early brachial dilatation (β = -0.286, p = 0.013). A close interplay between the peri-brachial fat and brachial dilatation can be translated into novel clinical tools to predict successful AVF maturation.Entities:
Mesh:
Year: 2020 PMID: 32123226 PMCID: PMC7051993 DOI: 10.1038/s41598-020-60734-8
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Baseline characteristics and vascular outcomes of patients who newly created AVFs.
| Variables | Total patients (n = 162) | Clinically functional AVFs until 8 weeks | ||
|---|---|---|---|---|
| Success (n = 141, 87.0%) | Failure (n = 21, 13.0%) | P | ||
| Age (years) | 64.1 ± 12.1 | 64.1 ± 11.1 | 65.5 ± 13.9 | 0.642 |
| Gender, male, n (%) | 98 (60.5) | 87 (61.7) | 11 (52.4) | 0.280 |
| BMI, kg/m2 | 25.1 ± 4.3 | 24.8 ± 3.7 | 25.4 ± 4.7 | 0.624 |
| Diabetes, n (%) | 103 (64.0) | 89 (63.6) | 14 (66.7) | 0.494 |
| Previous CAD, n (%) | 34 (20.9) | 27 (19.1) | 7 (33.3) | 0.177 |
| Cause of ESRD, n (%) | 0.405 | |||
| Diabetic | 98 (60.5) | 84 (59.6) | 14 (66.7) | |
| Hypertensive | 37 (22.8) | 33 (23.4) | 4 (19.0) | |
| Glomerulonephritis | 11 (6.8) | 9 (6.4) | 2 (9.5) | |
| Others | 16 (9.8) | 15 (9.9) | 1 (4.8) | |
| Systolic blood pressure (mmHg) | 145.1 ± 19.9 | 146.1 ± 19.9 | 140.6 ± 19.0 | 0.336 |
| Diastolic blood pressure (mmHg) | 76.5 ± 12.1 | 77.7 ± 12.7 | 72.2 ± 13.0 | 0.101 |
| Types | 0.212 | |||
| Forearm AVFs, n (%) | 91 (56.2) | 77 (84.6) | 14 (15.4) | |
| Upper arm AVFs, n (%) | 71 (43.8) | 64 (90.1) | 7 (9.9) | |
| WBC, cells/mm3 | 6,812 ± 1,870 | 6,924 ± 1,840 | 6,510 ± 2,010 | 0.450 |
| Hemoglobin (g/dL) | 9.4 ± 1.6 | 9.3 ± 1.4 | 9.8 ± 2.4 | 0.312 |
| Neutrophil, cells/mm3 | 4,708 ± 1,716 | 4,115 ± 1,814 | 4,852 ± 1,120 | 0.138 |
| N/L ratio | 4.2 ± 2.5 | 3.6 ± 2.1 | 4.5 ± 2.3 | 0.150 |
| BUN, mg/dL | 80.8 ± 30.2 | 79.3 ± 30.3 | 86.5 ± 29.2 | 0.402 |
| Creatinine, mg/dL | 7.6 ± 3.1 | 7.6 ± 3.3 | 7.6 ± 2.4 | 0.952 |
| Albumin, g/dL | 3.5 ± 0.5 | 3.5 ± 0.5 | 3.5 ± 0.5 | 0.957 |
| Total cholesterol, mg/dL | 152.7 ± 47.5 | 151.1 ± 50.4 | 156.0 ± 35.7 | 0.719 |
| Lean Tissue Index | 12.7 ± 5.3 | 12.4 ± 4.2 | 11.6 ± 5.0 | 0.353 |
| Fat Tissue Index | 11.6 ± 5.0 | 11.4 ± 4.7 | 13.0 ± 6.5 | 0.203 |
| Percentage of body fat (%) | ||||
| female | 29.3 ± 10.3 | 29.3 ± 10.1 | 29.6 ± 12.7 | 0.930 |
| male | 37.3 ± 9.8 | 37.1 ± 9.2 | 38.1 ± 13.2 | 0.787 |
| ECW/ICW ratio | 1.0 ± 0.2 | 1.0 ± 0.2 | 1.0 ± 0.2 | 0.924 |
| Overhydration, L | 2.2 ± 2.9 | 2.3 ± 2.9 | 1.6 ± 2.8 | 0.360 |
All data are expressed as mean ± SD. Abbreviations: BMI, body mass index; CAD, coronary artery disease; ESRD, end-stage renal disease; BUN, blood urea nitrogen; ECW, extracellular water; ICW, intracellular water.
Comparisons of pre- and 1-month postoperative US findings according to primary endpoint.
| Clinical characteristics | Failure of clinically functional AVFs until 8 weeks | ||
|---|---|---|---|
| Success (141, 87.0%) | Failure (21, 13.0%) | P | |
| Brachial artery | |||
| Diameter, mm | 4.18 ± 0.67 | 3.90 ± 0.61 | 0.082 |
| Peak systolic velocity, cm/s | 66.4 ± 19.4 | 60.3 ± 15.1 | 0.210 |
| Mean Velocity, cm/s | 9.6 ± 4.4 | 9.9 ± 4.9 | 0.791 |
| Flow Volume, mL/min | 74.4 ± 37.3 | 52.0 ± 30.5 | 0.016 |
| Calcification, n (%) | 5 (3.5) | 6 (28.5) | 0.005 |
| Radial artery, mm | |||
| Diameter, mm | 2.1 ± 0.3 | 2.0 ± 0.4 | 0.208 |
| Calcification, n (%) | 9 (6.3) | 3 (14.2) | 0.347 |
| Cephalic vein, mm | 2.9 ± 0.7 | 2.8 ± 0.5 | 0.542 |
| Brachial artery | |||
| Diameter, mm | 5.07 ± 0.71 | 4.50 ± 0.65 | 0.001 |
| Peak systolic velocity, cm/s | 169.8 ± 67.1 | 83.9 ± 54.5 | 0.035 |
| Mean Velocity, cm/s | 109.5 ± 49.1 | 61.4 ± 47.6 | 0.009 |
| Flow Volume, mL/min | 1300.2 ± 594.2 | 328.7 ± 225.8 | <0.001 |
| RI | 0.51 ± 0.09 | 0.86 ± 0.17 | 0.033 |
| Δ Diameter, median with IQR | 0.85 (0.52–1.22) | 0.43 (0.30–0.52) | 0.003 |
| Δ Diameter, % | 24.5 ± 17.7 | 13.8 ± 11.4 | 0.011 |
| Δ Flow volume, mL | 1235.7 ± 582.9 | 283.2 ± 179.6 | <0.001 |
Figure 1The role of early brachial dilatation for outcome prediction in hemodialysis patients. Comparison of brachial dilatation at 1-month after surgery between patients with or without maturation. (A) When early brachial dilatation was added to the predicting model, the AUC increased significantly. (B) Kaplan-Meier estimates for the patency rate. Patients with a brachial dilatation greater than 0.75 mm showed a 1.8-times higher rate of achieving a successful AVF than those without (C).
Figure 2The peribrachial fat thickness had a significantly negative asociation with an early brachial dilatation after AVF creation.
Correlation analysis.
| ∆ Brachial diameter | Peri-brachial fat thickness | Brachial calcification | ||||
|---|---|---|---|---|---|---|
| r | p | r | p | |||
| Age | −0.129 | 0.139 | 0.158 | 0.213 | −0.292 | 0.022 |
| Gender | 0.140 | 0.096 | 0.035 | 0.788 | −0.051 | 0.569 |
| DM | −0.260 | 0.001 | 0.215 | 0.062 | 0.113 | 0.183 |
| Hypertension | −0.049 | 0.554 | 0.260 | 0.022 | 0.094 | 0.268 |
| CAD | 0.059 | 0.472 | 0.234 | 0.040 | 0.070 | 0.412 |
| Systolic BP | −0.070 | 0.569 | 0.134 | 0.480 | −0.302 | 0.809 |
| Diastolic BP | 0.118 | 0.324 | 0.140 | 0.462 | −0.127 | 0.335 |
| BMI | 0.040 | 0.704 | 0.231 | 0.076 | −0.172 | 0.205 |
| AVF location | 0.181 | 0.027 | −0.091 | 0.432 | 0.139 | 0.101 |
| LTI | −0.153 | 0.127 | 0.069 | 0.625 | −0.182 | 0.068 |
| FTI | 0.032 | 0.740 | 0.031 | 0.830 | 0.100 | 0.319 |
| OH | −0.115 | 0.247 | −0.047 | 0.739 | −0.002 | 0.988 |
| Initial FV | −0.065 | 0.470 | 0.039 | 0.744 | −0.051 | 0.569 |
| Brachial calcification | −0.178 | 0.036 | 0.200 | 0.085 | — | — |
| Peri-brachial fat thickness | −0.301 | 0.008 | — | — | 0.200 | 0.085 |
| ∆ Brachial diameter | — | — | −0.301 | 0.008 | −0.178 | 0.036 |
| ∆ Brachial FV | 0.278 | 0.003 | 0.125 | 0.778 | 0.181 | 0.627 |
Abbreviations: DM, diabetes mellitus; BMI, body mass index; LTI, lean tissue index; FTI, fat tissue index; OH, overhydration; FV, flow volume.
Figure 3Representative imagings for peribrachial fat tissue and its association with brachial dilatation. Gross imaging at the time of surgery showed diffuse irregular fat deposit along the brachial artery (A) and it can be visualized in preoperative vascular mapping with US (B) Patients with brachial dilatation less than median level had a significantly thicker peribrachial fat (C).
Univariate and multivariate linear regression analysis: role of peri-brachial fat thickness and brachial calcification on brachial dilatation.
| ∆ Brachial diameter | Univariate analysis | Multivariate analysis | ||||||
|---|---|---|---|---|---|---|---|---|
| Model 1 | Model 2 | Model 3 | ||||||
| β | P | β | P | β | P | β | P | |
| Peri-brachial fat | −0.301 | 0.008 | −0.316 | 0.009 | −0.304 | 0.012 | −0.286 | 0.013 |
| Brachial calcification | −0.178 | 0.036 | −0.195 | 0.027 | −0.236 | 0.010 | −0.218 | 0.014 |
β, standardized regression coefficient.
Model 1, adjusted for age and gender.
Model 2, model 1 + adjustment for baseline brachial arterial FV and AVF location.
Model 3, model 2 + adjustment for comorbidities (diabetes, hypertension and CAD).